Nelmastobart in Combination With Trifluridine/ Tipiracil and Bevacizumab in Metastatic/ Recurrent Colorectal Cancer

NCT06873763 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

52

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Colorectal Cancer (CRC)
Recurrent Colorectal Cancer

Interventions

DRUG: Nelmastobart 800 mg+Trifluridine/Tipiracil+ Bevacizumab

Sponsor

STCube, Inc.